Beyond the Mammogram: What Proactive Breast Health Looks Like
A mammogram is a starting point. Learn about breast density, supplemental screening, hormone pathways, and lifestyle factors that shape your breast health.
October is Breast Cancer Awareness Month, and every year the message is familiar: schedule your mammogram.
That matters. Mammography remains one of the most effective tools for early detection, and staying current on your screenings is one of the most important things you can do for your breast health.
But for many women, the mammogram is where the conversation begins and ends. You schedule it, you get through it, you wait for results, and you move on. Unless something comes back abnormal, breast health does not come up again until next year.
A complete strategy involves more than one annual screening. It includes knowing your breast density, understanding your individual risk, choosing the right imaging for your body, and looking at the hormone and lifestyle factors that shape your risk over time.
This post covers each of those pieces. It is educational and is not a substitute for screening or for guidance from your own healthcare team.
Breast Density: The Variable Most Women Miss
If you have never been told your breast density, you are in good company. Many women go years without knowing it, even though it affects both their risk and the accuracy of their mammograms.
Breast density describes the proportion of fibrous and glandular tissue relative to fatty tissue. It is determined by mammogram, not by breast size or how your breasts feel on self-exam.
Roughly 40 to 50 percent of women in screening age ranges have dense breast tissue, which falls into category C or D on the four-tier scale.
Here is why it matters:
Since September 10, 2024, U.S. mammography facilities have been required to notify patients about their breast density in the results letter, so check your report or ask your imaging center.[2] If you are category C or D, ask your provider whether additional screening makes sense for you.
Screening Options Beyond the Standard Mammogram
“Alternatives” is a word I want to handle carefully. For most women, mammography stays the foundation of screening. But there are other tools that can add to it, or that may fit your situation better, and many women are never told about them.
| Option | What to Know |
|---|---|
| 3D Mammography (Tomosynthesis) | It takes images in layers. In a large study, adding tomosynthesis to standard digital mammography increased cancer detection and reduced the number of women called back for extra imaging.[3] It is available at many imaging centers and is often a simple upgrade from standard screening. |
| Breast Ultrasound | Often used as a supplement for women with dense breasts. In a trial of women at elevated risk, adding ultrasound to mammography found additional cancers, though it also led to more false alarms.[4] |
| Breast MRI | The most sensitive imaging tool available, and the one most often recommended for higher-risk women, such as those with a BRCA mutation or a strong family history.[4] In a large randomized trial of women with extremely dense breasts and a normal mammogram, adding MRI found additional cancers and reduced the number of cancers diagnosed between screening rounds.[5] Shorter “abbreviated” MRI protocols are becoming more available. |
| Contrast-Enhanced Mammography | A newer option at some centers that uses contrast dye with mammography images and may help in dense tissue. |
| Clinical Breast Exams | A hands-on exam by a trained clinician is a reasonable part of care for many women, and I recommend arranging one with a local provider. |
| A Formal Risk Assessment | Tools used by many clinicians estimate your lifetime risk from your personal and family history. That number often decides which of the options above make sense for you. |
The U.S. Preventive Services Task Force recommends screening mammography every two years for women ages 40 to 74, and it concluded that the evidence is currently insufficient to recommend for or against supplemental imaging in women with dense breasts.[6] That is not a “no.” It is a reason to talk with your provider about your own risk, your density, and your preferences.
You may see thermography marketed as a radiation-free alternative to mammography. The FDA has warned that thermography should not be used in place of mammography to screen for or diagnose breast cancer.[7]
Which of these fits you is a decision to make with your primary care provider or a breast imaging specialist.
Your Breast Health Toolkit
A screening chart by age and risk, a breast density guide, and the questions to ask at your next appointment, all in one place.
Download Your Breast Health Toolkit →Risk Factors: What You Can’t Change and What You Can
What You Can’t Change
Family history, genetic mutations like BRCA1 and BRCA2, age at first period, and age at menopause all play a role.
Having one first-degree relative with breast cancer is associated with roughly 1.8 times the risk of a woman with no affected relatives, and the risk rises with more affected relatives.[8] Knowing where you stand helps your provider tailor your screening plan.
What You Can Influence
A meaningful portion of risk is shaped by everyday choices:
- Physical activity. In a large pooled analysis, higher levels of physical activity were associated with roughly 10 percent lower breast cancer risk.[9] General guidelines recommend at least 150 minutes per week of moderate activity.
- Alcohol. In a collaborative analysis of 53 studies, breast cancer risk rose about 7 percent for each additional 10 grams of alcohol per day.[10] A standard U.S. drink contains about 14 grams.
- Body composition, sleep, and chronic stress all contribute.
This is not about perfection. It is about being intentional with the factors you can actually influence.
The Functional Medicine Layer: Your Hormone Pathways
This is where my work comes in. Imaging looks for changes in the breast tissue. Functional medicine asks a different question: what is happening in the hormone, metabolic, and lifestyle environment around that tissue?
Here is what I look at:
How Your Body Metabolizes Estrogen
Estrogen is broken down through several pathways, and the pattern matters more than a single estrogen number. A DUTCH test (a dried urine test) shows how estrogen is being metabolized, including which breakdown pathways your body favors and how well methylation is working to clear them. It can also show cortisol patterns, progesterone, and androgens.
Insulin and Blood Sugar
In a large analysis of postmenopausal women, higher fasting insulin levels were associated with a higher risk of breast cancer, particularly in women not using hormone therapy.[11] Insulin can be elevated even when fasting glucose looks normal, so fasting insulin and related markers add context.
Gut and Liver Clearance
Estrogen has to be cleared through the liver and gut. Constipation, gut imbalances, and a sluggish clearance pathway can affect how much estrogen recirculates.
Nutrients That Support These Pathways
Vitamin D, which is frequently low and rarely checked, along with B vitamins, magnesium, and omega-3 status, are all worth reviewing.
Alcohol, Sleep, Stress, and Body Composition
The same lifestyle factors listed above, looked at through the lens of how they affect your hormone balance.
What Hormone Testing Does and Does Not Do
I want to be clear about what this does and does not do. Hormone testing like the DUTCH is not a cancer screening test, and it does not predict or diagnose breast cancer. It does not replace imaging.
What it does is show how your body is handling hormones right now, so we can build a lifestyle and nutrition plan around your specific pattern instead of a generic list.
Nutrition as a Layer of Support
There is no single food that prevents breast cancer. But dietary patterns matter.
Cruciferous vegetables like broccoli, cauliflower, and Brussels sprouts contain compounds that support healthy estrogen metabolism.
Omega-3 fatty acids from fish, walnuts, and flaxseed help manage inflammation.
Fiber supports clearance through the gut.
Vitamin D deserves a check, since low levels are common.
On the other side, ultra-processed foods contribute to chronic inflammation, and endocrine disruptors found in certain plastics and personal care products can interfere with hormone signaling over time. You do not need to overhaul your life overnight. Knowing where targeted changes can support your body gives you more agency than most awareness campaigns offer.
Hormone Therapy
For women in perimenopause or menopause, the question of hormone therapy often carries more anxiety than almost any other health decision. Much of that anxiety traces back to the 2002 Women’s Health Initiative (WHI) study, which was widely read as proof that hormones cause breast cancer.[12]
The full picture is more nuanced than the headlines:
- 1
One Specific Combination
That study tested one specific combination: oral conjugated equine estrogen plus a synthetic progestin (medroxyprogesterone acetate). It does not speak to every form of hormone therapy.[12]
- 2
Estrogen Alone Looked Different
In the WHI trial of women who had a hysterectomy, estrogen alone was not associated with an increase in breast cancer.[13] In long-term follow-up, estrogen plus progestin was associated with a higher incidence of breast cancer, while estrogen alone was associated with a lower incidence.[14]
- 3
The Type of Progesterone Matters
Body-identical (micronized) progesterone may carry less risk than synthetic progestins. In the large French E3N cohort, estrogen combined with micronized progesterone was associated with little to no increase in risk, compared with a higher risk for synthetic progestins.[15] That is observational data, and randomized trial evidence is more limited.
- 4
Timing and Type Matter
Current guidance from The Menopause Society (formerly NAMS) says the benefit-risk balance is most favorable for women who start hormone therapy before age 60 or within 10 years of menopause, and that risk depends on the type of hormone, the dose, the route, and the duration.[16]
A generalized fear is not a good basis for a decision, and neither is a generalized “it’s safe.”
Your personal risk profile, your symptoms, and the current evidence should drive the choice.
The conversation is different. Systemic hormone therapy is generally not recommended after breast cancer, and nonhormonal options are the first choice for symptoms like hot flashes. In some cases, low-dose vaginal estrogen for urogenital symptoms may be considered after a conversation with your oncology team.[16] Any decision like this needs to involve your oncologist.
And the other side deserves equal space in the conversation. Untreated menopause symptoms, bone density loss, and urogenital changes are real and well documented, and they affect quality of life.[16] Avoiding hormone therapy is also a decision with consequences, and it should be made with information, not fear.
What Proactive Care Looks Like
Proactive breast health means:
- Knowing your breast density and what it means for your screening plan
- Understanding your individual risk, including the factors you carry and the ones you can influence
- Choosing imaging that fits your body, working with a local provider for exams and screening
- Looking at your hormone, metabolic, and lifestyle picture, which is where I come in
- Having honest conversations about screening, risk, and what your body needs during perimenopause and menopause
Download the Guide
We put together Your Breast Health Toolkit to help you pull all of this together in one place and bring better questions to your next appointment.
Download Your Breast Health Toolkit →Want to Talk Through Your Hormone Health?
If you’d like to talk through your hormone health, I also offer a free discovery call. As a virtual practice, I focus on hormone balance, nutrition, and lifestyle, and I work alongside your local providers for imaging and exams.
Book Your Free Discovery Call →Frequently Asked Questions
What is breast density, and why does it matter?
Breast density describes the proportion of fibrous and glandular tissue relative to fatty tissue, and it is determined by mammogram, not by breast size or how your breasts feel. Roughly 40 to 50 percent of women in screening age ranges have dense breasts (category C or D). Dense tissue is associated with higher breast cancer risk on its own, and it makes cancers harder to see on a mammogram because dense tissue and tumors both appear white.
Should I get extra screening if I have dense breasts?
It depends on your individual risk. The U.S. Preventive Services Task Force found the evidence currently insufficient to recommend for or against supplemental imaging in women with dense breasts, which is a reason to talk with your provider about your risk, your density, and your preferences. Options that can add to mammography include 3D mammography, breast ultrasound, breast MRI, and contrast-enhanced mammography.
Is thermography a safe alternative to a mammogram?
No. The FDA has warned that thermography should not be used in place of mammography to screen for or diagnose breast cancer.
Can a DUTCH test detect breast cancer?
No. Hormone testing like the DUTCH is not a cancer screening test, and it does not predict or diagnose breast cancer or replace imaging. It shows how your body is handling hormones right now, including which estrogen breakdown pathways your body favors, so a lifestyle and nutrition plan can be built around your pattern.
Does hormone therapy cause breast cancer?
The answer depends on the type, timing, dose, route, and duration. The 2002 WHI study tested one combination, oral conjugated equine estrogen plus a synthetic progestin. In WHI long-term follow-up, estrogen plus progestin was associated with a higher incidence of breast cancer, while estrogen alone was associated with a lower incidence. The Menopause Society says the benefit-risk balance is most favorable when hormone therapy starts before age 60 or within 10 years of menopause. Your personal risk profile should drive the decision.
For educational purposes only. Not a diagnosis, and not a substitute for medical screening or advice from your healthcare provider. Talk with your provider about which screening is right for you.
- Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227-236.
- U.S. Food and Drug Administration. Important information: final rule to amend the Mammography Quality Standards Act (MQSA); breast density notification, effective September 10, 2024. https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-and-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
- Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499-2507.
- Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394-1404. https://pubmed.ncbi.nlm.nih.gov/22474203/
- Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 2019;381(22):2091-2102.
- U.S. Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918-1930.
- U.S. Food and Drug Administration. FDA warns against the use of thermography in lieu of mammography to detect, diagnose, or screen for breast cancer. News release, February 25, 2019. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631957.htm
- Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389-1399.
- Moore SC, Lee IM, Weiderpass E, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176(6):816-825. https://pubmed.ncbi.nlm.nih.gov/27183032/
- Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer: collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234-1245. https://pubmed.ncbi.nlm.nih.gov/12439712/
- Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48-60.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. https://pubmed.ncbi.nlm.nih.gov/12117397/
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
- Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. https://pubmed.ncbi.nlm.nih.gov/32721007/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111.
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
